Literature DB >> 11342577

A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function.

X Feng1, D V Novack, R Faccio, D S Ory, K Aya, M I Boyer, K P McHugh, F P Ross, S L Teitelbaum.   

Abstract

Osteoclastic bone resorption requires cell-matrix contact, an event mediated by the alpha v beta 3 integrin. The structural components of the integrin that mediate osteoclast function are, however, not in hand. To address this issue, we generated mice lacking the beta 3 integrin gene, which have dysfunctional osteoclasts. Here, we show the full rescue of beta 3(-/-) osteoclast function following expression of a full-length beta 3 integrin. In contrast, truncated beta 3, lacking a cytoplasmic domain (h beta 3c), is completely ineffective in restoring function to beta 3(-/-) osteoclasts. To identify the components of the beta 3 cytoplasmic domain regulating osteoclast function, we generated six point mutants known, in other circumstances, to mediate beta integrin signaling. Of the six, only the S(752)P substitution, which also characterizes a form of the human bleeding disorder Glanzmann's thrombasthenia, fails to rescue beta 3(-/-) osteoclasts or restore ligand-activated signaling in the form of c-src activation. Interestingly, the double mutation Y(747)F/Y(759)F, which disrupts platelet function, does not affect the osteoclast. Thus similarities and distinctions exist in the mechanisms by which the beta 3 integrin regulates platelets and osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342577      PMCID: PMC209281          DOI: 10.1172/JCI12040

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Avian osteoblast conditioned media stimulate bone resorption by targeting multinucleating osteoclast precursors.

Authors:  E M Greenfield; J I Alvarez; E A McLaurine; M J Oursler; H C Blair; P Osdoby; S L Teitelbaum; F P Ross
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

2.  Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.

Authors:  S M Violette; W Guan; C Bartlett; J A Smith; C Bardelay; E Antoine; R J Rickles; E Mandine; M R van Schravendijk; S E Adams; B A Lynch; W C Shakespeare; M Yang; V A Jacobsen; C S Takeuchi; K J Macek; R S Bohacek; D C Dalgarno; M Weigele; D Lesuisse; T K Sawyer; R Baron
Journal:  Bone       Date:  2001-01       Impact factor: 4.398

Review 3.  Integrins: versatility, modulation, and signaling in cell adhesion.

Authors:  R O Hynes
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

4.  Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival.

Authors:  L Xing; A M Venegas; A Chen; L Garrett-Beal; B F Boyce; H E Varmus; P L Schwartzberg
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

5.  A point mutation in the integrin beta 3 cytoplasmic domain (S752-->P) impairs bidirectional signaling through alpha IIb beta 3 (platelet glycoprotein IIb-IIIa).

Authors:  Y P Chen; T E O'Toole; J Ylänne; J P Rosa; M H Ginsberg
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

6.  Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.

Authors:  M A Horton; M L Taylor; T R Arnett; M H Helfrich
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

7.  Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.

Authors:  Y P Chen; I Djaffar; D Pidard; B Steiner; A M Cieutat; J P Caen; J P Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts and mouse-derived osteoclast-like cells.

Authors:  Z Zimolo; G Wesolowski; H Tanaka; J L Hyman; J R Hoyer; G A Rodan
Journal:  Am J Physiol       Date:  1994-02

9.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.

Authors:  P Soriano; C Montgomery; R Geske; A Bradley
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Integrin receptor-mediated mobilisation of intranuclear calcium in rat osteoclasts.

Authors:  G Shankar; I Davison; M H Helfrich; W T Mason; M A Horton
Journal:  J Cell Sci       Date:  1993-05       Impact factor: 5.285

View more
  54 in total

1.  Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Joel Jules; Duorong Xu; Shaokai Luo; Shi Wei; Xu Feng
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

2.  Src kinase activation by direct interaction with the integrin beta cytoplasmic domain.

Authors:  Elena G Arias-Salgado; Sergio Lizano; Sugata Sarkar; Joan S Brugge; Mark H Ginsberg; Sanford J Shattil
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

3.  Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members.

Authors:  Duorong Xu; Zhenqi Shi; Jay McDonald; George Pan; Xuemei Cao; Xueqing Yu; Xu Feng
Journal:  Biochem J       Date:  2004-10-15       Impact factor: 3.857

Review 4.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

5.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Authors:  Joel Jules; Shunqing Wang; Zhenqi Shi; Jianzhong Liu; Shi Wei; Xu Feng
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

6.  Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity.

Authors:  Angela Bruzzaniti; Lynn Neff; Archana Sanjay; William C Horne; Pietro De Camilli; Roland Baron
Journal:  Mol Biol Cell       Date:  2005-05-04       Impact factor: 4.138

7.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

8.  [Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].

Authors:  Lin Jueshan; Dong Wei; Xu Chunfeng; Sun Hong; Feng Xiaojie; Qi Mengchun
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2014-12

9.  A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans.

Authors:  Nikolay L Malinin; Li Zhang; Jeongsuk Choi; Alieta Ciocea; Olga Razorenova; Yan-Qing Ma; Eugene A Podrez; Michael Tosi; Donald P Lennon; Arnold I Caplan; Susan B Shurin; Edward F Plow; Tatiana V Byzova
Journal:  Nat Med       Date:  2009-02-22       Impact factor: 53.440

10.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.